tirapazamine has been researched along with fosbretabulin* in 2 studies
2 other study(ies) available for tirapazamine and fosbretabulin
| Article | Year |
|---|---|
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Hypoxia; Colchicine; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; NADPH-Ferrihemoprotein Reductase; Prodrugs; Stilbenes; Tubulin | 2020 |
Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
Hypoxia-activated prodrugs (HAPs) have the potential to selectively kill hypoxic cells and convert tumor hypoxia from a problem to a selective treatment advantage. However, HAPs are unsuccessful in most clinical trials owing to inadequate hypoxia within the treated tumors, as implied by a further substudy of a phase II clinical trial. Here, a novel strategy for the combination of HAPs plus vascular disrupting agent (VDA) nanomedicine for efficacious solid tumor therapy is developed. An effective VDA nanomedicine of poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol)/combretastatin A4 (CA4-NPs) is prepared and can selectively enhance tumor hypoxia and boost a typical HAP tirapazamine (TPZ) therapy against metastatic 4T1 breast tumors. After treatment with the combination of TPZ plus CA4-NPs, complete tumor reduction is observed in 4T1 xenograft mice (initial tumor volume is 180 mm Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Mice; Mice, Inbred BALB C; Nanomedicine; Neoplasm Metastasis; Prodrugs; Stilbenes; Tirapazamine; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2019 |